ESTRO 2024 - Abstract Book

S2393

Clinical - Urology

ESTRO 2024

Conclusion:

The combined PSMA PET/mpMRI and PET/CT protocol detected recurrence in almost 50 % of the patients. In this group, PSMA PET resulted in upgrading of disease stage and subsequent change of management for more than 30 % of the patients.

Keywords: prostate cancer, PSMA-PET

References:

[1]Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II — 2020 Update: treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79:263 – 82.

[2] European guidelines update on PSMA PET/CT for prostate cancer staging — snap back to reality

Fabrizia Gelardi, Alberto Briganti, Cristiano Pini, Gaia Ninatti, Giorgio Gandaglia, Francesco Montorsi & Arturo Chiti. European Journal of Nuclear Medicine and Molecular Imaging volume 50, pages2572 – 2575 (2023)

1102

Digital Poster

Decision Regret after Radiotherapy of Oligometastatic Prostate Cancer Patients